Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
M Sherman, E M Yoshida, M Deschenes, M Krajden, V G Bain, K Peltekian, F Anderson, K Kaita, S Simonyi, R Balshaw, S S Lee, and the Canadian Pegasys Study Group
Competing interests: MS, advisor and speakers bureau for Roche.
EMY, Honoraria for lectures sponsored by Roche and Schering Plough; Advisor to Roche; Unrestricted research grants from Roche, Schering Plough, Fujisawa, Pfizer, GlaxoSmithKline; Investigator in trials sponsored by Roche, Schering Ploughm Human Genome Sciences, Idenix, Microgenix, Fujisawa, Novartis, Wyeth.
MD, no conflicts of interest to declare.
MK, unrestricted research grants from Roche, Schering Plough.
VGB, no conflicts of interest to declare.
KP, no conflicts of interest to declare.
FA, no conflicts of interest to declare.
KK, no conflicts of interest to declare.
SS, Roche employee.
SSL, research grants from Roche, speakers bureau and consulting for Roche.
